PUNE, India, September 26, 2016 /PRNewswire/ --
RnRMarketResearch.com adds "Optic Neuropathy - Pipeline Review, H2 2016" market research report with comprehensive information on the therapeutic development for Optic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Optic Neuropathy and special features on late-stage and discontinued projects.
Complete report on H2 2016 pipeline review of Optic Neuropathy with 22 market data tables and 15 figures, spread across 59 pages is available at http://www.rnrmarketresearch.com/optic-neuropathy-pipeline-review-h2-2016-market-report.html .
Optic Neuropathy Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer treating drugs, stress related chemicals, some antibiotics and cyanogens.
Optic Neuropathy pipeline therapeutics constitutes close to 14 molecules. Out of which approximately 8 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.
Companies discussed in this Optic Neuropathy Pipeline Review, H2 2016 report include Amgen Inc., BioAxone BioSciences, Inc., Inotek Pharmaceuticals Corporation, Ironwood Pharmaceuticals, Inc., PharmatrophiX, Inc., Quark Pharmaceuticals, Inc. and Regenera Pharma Ltd. Drug Profiles mentioned in this research report are BA-240, IWP-953, LM-22A4, Monoclonal Antibodies to Inhibit Sema3A for Glaucoma and Optic Neuropathy, NT-501, QPI-1007, RPh-201, Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy, Small Molecules for CNS Disorders and Ophthalmology, Small Molecules for Neurological and Ophthalmological Diseases, Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders, Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy, trabodenoson and WSTB-1.
Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=696554 .
This research report outlays comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects.
Scope of this report: The report provides a snapshot of the global therapeutic landscape of Optic Neuropathy and reviews pipeline therapeutics for Optic Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Optic Neuropathy therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Optic Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Optic Neuropathy.
Another newly published market research report titled Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are Aciont Inc., Adverum Biotechnologies, Inc., Allergan Plc, Alteogen Inc., Amakem NV, Ampio Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc., Apexigen, Inc., Applied Genetic Technologies Corporation, Benitec Biopharma Limited, Boehringer Ingelheim GmbH, Cell Medica Limited, Charlesson LLC., Cipla Ltd., Clanotech AB, Clearside BioMedical, Inc., Clonz Biotech Private Limited and Coherus BioSciences, Inc. Wet (Neovascular / Exudative) Macular Degeneration Pipeline market research report of 267 pages is available at http://www.rnrmarketresearch.com/wet-neovascular-exudative-macular-degeneration-pipeline-review-h2-2016-market-report.html .
Explore more reports on Ophthalmology therapeutics.
RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers.
2nd floor, Metropole,
Next to Inox theatre, Bund garden road,
+ 1 888 391 5441
SOURCE RnR Market Research